It was not that long after Deborah Dunsire took hold of the reins at Lundbeck Inc. that she knew she had a tough job on her hands. Strategic cost-cutting decisions by the previous ceo Kare Schultz, he left to join Teva Pharmaceutical Industries Ltd., had steadied the ship financially but the impending loss of exclusivity of the company’s best-selling drug, Onfi, the epilepsy treatment, was always going to be a major challenge.
Barely two months into the role and the company revealed at the end of October that its most advanced clinical...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
